BioNTech (BNTX) to Release Earnings on Monday

BioNTech (NASDAQ:BNTX) will release its earnings data before the market opens on Monday, November 4th. Analysts expect BioNTech to post earnings of ($1.06) per share for the quarter. BioNTech has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The company had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company’s revenue for the quarter was down 23.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.86) earnings per share. On average, analysts expect BioNTech to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

BioNTech Price Performance

BioNTech stock opened at $111.48 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The stock has a market cap of $26.51 billion, a price-to-earnings ratio of -49.33 and a beta of 0.24. The firm has a 50-day moving average of $109.72 and a two-hundred day moving average of $95.77. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49.

Analysts Set New Price Targets

BNTX has been the topic of several research analyst reports. JPMorgan Chase & Co. raised BioNTech from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $91.00 to $125.00 in a research note on Monday, September 16th. UBS Group raised their price target on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and upped their price objective for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, TD Cowen boosted their price target on shares of BioNTech from $85.00 to $132.00 and gave the company a “hold” rating in a report on Monday, October 21st. Five research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $135.54.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.